The Innate Immune System: Fighting on the Front Lines or Fanning the Flames of COVID-19?
Identifieur interne : 000229 ( Main/Exploration ); précédent : 000228; suivant : 000230The Innate Immune System: Fighting on the Front Lines or Fanning the Flames of COVID-19?
Auteurs : Julia L. Mckechnie [États-Unis] ; Catherine A. Blish [États-Unis]Source :
- Cell host & microbe [ 1934-6069 ] ; 2020.
Descripteurs français
- KwdFr :
- Cellules myéloïdes (immunologie), Cellules tueuses naturelles (immunologie), Cytokines (immunologie), Humains (MeSH), Immunité innée (MeSH), Infections à coronavirus (anatomopathologie), Infections à coronavirus (immunologie), Infections à coronavirus (traitement médicamenteux), Pandémies (MeSH), Pneumopathie virale (anatomopathologie), Pneumopathie virale (immunologie), Pneumopathie virale (traitement médicamenteux), Protéines du système du complément (immunologie).
- MESH :
- anatomopathologie : Infections à coronavirus, Pneumopathie virale.
- immunologie : Cellules myéloïdes, Cellules tueuses naturelles, Cytokines, Infections à coronavirus, Pneumopathie virale, Protéines du système du complément.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- Humains, Immunité innée, Pandémies.
English descriptors
- KwdEn :
- COVID-19 (MeSH), Complement System Proteins (immunology), Coronavirus Infections (drug therapy), Coronavirus Infections (immunology), Coronavirus Infections (pathology), Cytokines (immunology), Humans (MeSH), Immunity, Innate (MeSH), Killer Cells, Natural (immunology), Myeloid Cells (immunology), Pandemics (MeSH), Pneumonia, Viral (drug therapy), Pneumonia, Viral (immunology), Pneumonia, Viral (pathology).
- MESH :
- chemical , immunology : Complement System Proteins, Cytokines.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- immunology : Coronavirus Infections, Killer Cells, Natural, Myeloid Cells, Pneumonia, Viral.
- pathology : Coronavirus Infections, Pneumonia, Viral.
- COVID-19, Humans, Immunity, Innate, Pandemics.
Abstract
The coronavirus disease 2019 (COVID-19) pandemic caused by SARS-CoV-2 has had devastating global impacts and will continue to have dramatic effects on public health for years to come. A better understanding of the immune response to SARS-CoV-2 will be critical for the application and development of therapeutics. The degree to which the innate immune response confers protection or induces pathogenesis through a dysregulated immune response remains unclear. In this review, we discuss what is known about the role of the innate immune system during SARS-CoV-2 infection, suggest directions for future studies, and evaluate proposed COVID-19 immunomodulating therapeutics.
DOI: 10.1016/j.chom.2020.05.009
PubMed: 32464098
PubMed Central: PMC7237895
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The Innate Immune System: Fighting on the Front Lines or Fanning the Flames of COVID-19?</title><author><name sortKey="Mckechnie, Julia L" sort="Mckechnie, Julia L" uniqKey="Mckechnie J" first="Julia L" last="Mckechnie">Julia L. Mckechnie</name><affiliation wicri:level="2"><nlm:affiliation>Program in Immunology, Stanford University School of Medicine, Stanford, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Program in Immunology, Stanford University School of Medicine, Stanford, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Blish, Catherine A" sort="Blish, Catherine A" uniqKey="Blish C" first="Catherine A" last="Blish">Catherine A. Blish</name><affiliation wicri:level="2"><nlm:affiliation>Program in Immunology, Stanford University School of Medicine, Stanford, CA, USA; Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA; Chan Zuckerberg Biohub, San Francisco, CA, USA. Electronic address: cblish@stanford.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Program in Immunology, Stanford University School of Medicine, Stanford, CA, USA; Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA; Chan Zuckerberg Biohub, San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32464098</idno><idno type="pmid">32464098</idno><idno type="doi">10.1016/j.chom.2020.05.009</idno><idno type="pmc">PMC7237895</idno><idno type="wicri:Area/Main/Corpus">000677</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000677</idno><idno type="wicri:Area/Main/Curation">000677</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000677</idno><idno type="wicri:Area/Main/Exploration">000677</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The Innate Immune System: Fighting on the Front Lines or Fanning the Flames of COVID-19?</title><author><name sortKey="Mckechnie, Julia L" sort="Mckechnie, Julia L" uniqKey="Mckechnie J" first="Julia L" last="Mckechnie">Julia L. Mckechnie</name><affiliation wicri:level="2"><nlm:affiliation>Program in Immunology, Stanford University School of Medicine, Stanford, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Program in Immunology, Stanford University School of Medicine, Stanford, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Blish, Catherine A" sort="Blish, Catherine A" uniqKey="Blish C" first="Catherine A" last="Blish">Catherine A. Blish</name><affiliation wicri:level="2"><nlm:affiliation>Program in Immunology, Stanford University School of Medicine, Stanford, CA, USA; Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA; Chan Zuckerberg Biohub, San Francisco, CA, USA. Electronic address: cblish@stanford.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Program in Immunology, Stanford University School of Medicine, Stanford, CA, USA; Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA; Chan Zuckerberg Biohub, San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author></analytic><series><title level="j">Cell host & microbe</title><idno type="eISSN">1934-6069</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>COVID-19 (MeSH)</term><term>Complement System Proteins (immunology)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (immunology)</term><term>Coronavirus Infections (pathology)</term><term>Cytokines (immunology)</term><term>Humans (MeSH)</term><term>Immunity, Innate (MeSH)</term><term>Killer Cells, Natural (immunology)</term><term>Myeloid Cells (immunology)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (immunology)</term><term>Pneumonia, Viral (pathology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Cellules myéloïdes (immunologie)</term><term>Cellules tueuses naturelles (immunologie)</term><term>Cytokines (immunologie)</term><term>Humains (MeSH)</term><term>Immunité innée (MeSH)</term><term>Infections à coronavirus (anatomopathologie)</term><term>Infections à coronavirus (immunologie)</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Pandémies (MeSH)</term><term>Pneumopathie virale (anatomopathologie)</term><term>Pneumopathie virale (immunologie)</term><term>Pneumopathie virale (traitement médicamenteux)</term><term>Protéines du système du complément (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Complement System Proteins</term><term>Cytokines</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Cellules myéloïdes</term><term>Cellules tueuses naturelles</term><term>Cytokines</term><term>Infections à coronavirus</term><term>Pneumopathie virale</term><term>Protéines du système du complément</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Coronavirus Infections</term><term>Killer Cells, Natural</term><term>Myeloid Cells</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" xml:lang="en"><term>COVID-19</term><term>Humans</term><term>Immunity, Innate</term><term>Pandemics</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Immunité innée</term><term>Pandémies</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The coronavirus disease 2019 (COVID-19) pandemic caused by SARS-CoV-2 has had devastating global impacts and will continue to have dramatic effects on public health for years to come. A better understanding of the immune response to SARS-CoV-2 will be critical for the application and development of therapeutics. The degree to which the innate immune response confers protection or induces pathogenesis through a dysregulated immune response remains unclear. In this review, we discuss what is known about the role of the innate immune system during SARS-CoV-2 infection, suggest directions for future studies, and evaluate proposed COVID-19 immunomodulating therapeutics.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32464098</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>19</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1934-6069</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>6</Issue><PubDate><Year>2020</Year><Month>06</Month><Day>10</Day></PubDate></JournalIssue><Title>Cell host & microbe</Title><ISOAbbreviation>Cell Host Microbe</ISOAbbreviation></Journal><ArticleTitle>The Innate Immune System: Fighting on the Front Lines or Fanning the Flames of COVID-19?</ArticleTitle><Pagination><MedlinePgn>863-869</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S1931-3128(20)30291-2</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.chom.2020.05.009</ELocationID><Abstract><AbstractText>The coronavirus disease 2019 (COVID-19) pandemic caused by SARS-CoV-2 has had devastating global impacts and will continue to have dramatic effects on public health for years to come. A better understanding of the immune response to SARS-CoV-2 will be critical for the application and development of therapeutics. The degree to which the innate immune response confers protection or induces pathogenesis through a dysregulated immune response remains unclear. In this review, we discuss what is known about the role of the innate immune system during SARS-CoV-2 infection, suggest directions for future studies, and evaluate proposed COVID-19 immunomodulating therapeutics.</AbstractText><CopyrightInformation>Copyright © 2020 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McKechnie</LastName><ForeName>Julia L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Program in Immunology, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blish</LastName><ForeName>Catherine A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Program in Immunology, Stanford University School of Medicine, Stanford, CA, USA; Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA; Chan Zuckerberg Biohub, San Francisco, CA, USA. Electronic address: cblish@stanford.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>DP1 DA046089</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AI007290</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI007290</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Host Microbe</MedlineTA><NlmUniqueID>101302316</NlmUniqueID><ISSNLinking>1931-3128</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-36-7</RegistryNumber><NameOfSubstance UI="D003165">Complement System Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003165" MajorTopicYN="N">Complement System Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007113" MajorTopicYN="Y">Immunity, Innate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007694" MajorTopicYN="N">Killer Cells, Natural</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D022423" MajorTopicYN="N">Myeloid Cells</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">COVID-19</Keyword><Keyword MajorTopicYN="Y">SARS-CoV-2</Keyword><Keyword MajorTopicYN="Y">complement</Keyword><Keyword MajorTopicYN="Y">cytokines</Keyword><Keyword MajorTopicYN="Y">innate immune response</Keyword><Keyword MajorTopicYN="Y">myeloid cells</Keyword><Keyword MajorTopicYN="Y">natural killer cells</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>04</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>05</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>05</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32464098</ArticleId><ArticleId IdType="pii">S1931-3128(20)30291-2</ArticleId><ArticleId IdType="doi">10.1016/j.chom.2020.05.009</ArticleId><ArticleId IdType="pmc">PMC7237895</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Am J Respir Crit Care Med. 2020 May 15;201(10):1299-1300</Citation><ArticleIdList><ArticleId IdType="pubmed">32228035</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2020 Apr;26(4):453-455</Citation><ArticleIdList><ArticleId IdType="pubmed">32284614</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Immunol. 2017 Dec 06;8:1707</Citation><ArticleIdList><ArticleId IdType="pubmed">29270173</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Microbiol Rev. 2011 Jan;24(1):210-29</Citation><ArticleIdList><ArticleId IdType="pubmed">21233513</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Host Microbe. 2020 Jun 10;27(6):879-882.e2</Citation><ArticleIdList><ArticleId IdType="pubmed">32359396</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Urol. 2020 Jun;17(6):316-317</Citation><ArticleIdList><ArticleId IdType="pubmed">32341531</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Apr 30;382(18):1708-1720</Citation><ArticleIdList><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Clin Pathol. 2004 Apr;121(4):507-11</Citation><ArticleIdList><ArticleId IdType="pubmed">15080302</ArticleId></ArticleIdList></Reference><Reference><Citation>Chest. 2020 Jul;158(1):195-205</Citation><ArticleIdList><ArticleId IdType="pubmed">32224074</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 May;55(5):105938</Citation><ArticleIdList><ArticleId IdType="pubmed">32171740</ArticleId></ArticleIdList></Reference><Reference><Citation>Tissue Antigens. 2005 Oct;66(4):291-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16185324</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2020 Apr 27;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32338708</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Microbes Infect. 2020 Dec;9(1):761-770</Citation><ArticleIdList><ArticleId IdType="pubmed">32228226</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Rheumatol. 2020 Mar;16(3):155-166</Citation><ArticleIdList><ArticleId IdType="pubmed">32034323</ArticleId></ArticleIdList></Reference><Reference><Citation>Med J Aust. 2020 May;212(9):416-420</Citation><ArticleIdList><ArticleId IdType="pubmed">32266987</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Oncol. 2019 Nov 07;9:1186</Citation><ArticleIdList><ArticleId IdType="pubmed">31788449</ArticleId></ArticleIdList></Reference><Reference><Citation>Intensive Care Med. 2020 May;46(5):846-848</Citation><ArticleIdList><ArticleId IdType="pubmed">32125452</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Pathog. 2009 Oct;5(10):e1000636</Citation><ArticleIdList><ArticleId IdType="pubmed">19851468</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2020 Apr;20(4):400-402</Citation><ArticleIdList><ArticleId IdType="pubmed">32113509</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2010 Sep;84(17):8753-64</Citation><ArticleIdList><ArticleId IdType="pubmed">20573835</ArticleId></ArticleIdList></Reference><Reference><Citation>J Microbiol Immunol Infect. 2020 Jun;53(3):368-370</Citation><ArticleIdList><ArticleId IdType="pubmed">32205092</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Mol Immunol. 2020 May;17(5):533-535</Citation><ArticleIdList><ArticleId IdType="pubmed">32203188</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2020 Jul;26(7):1070-1076</Citation><ArticleIdList><ArticleId IdType="pubmed">32514174</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Med. 2020 May 4;217(5):</Citation><ArticleIdList><ArticleId IdType="pubmed">32289152</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Feb 15;395(10223):497-506</Citation><ArticleIdList><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Immunol. 2020 May 01;11:827</Citation><ArticleIdList><ArticleId IdType="pubmed">32425950</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2005 May 15;191(10):1697-704</Citation><ArticleIdList><ArticleId IdType="pubmed">15838797</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Host Microbe. 2020 Jun 10;27(6):883-890.e2</Citation><ArticleIdList><ArticleId IdType="pubmed">32407669</ArticleId></ArticleIdList></Reference><Reference><Citation>Microbes Infect. 2005 Mar;7(3):427-36</Citation><ArticleIdList><ArticleId IdType="pubmed">15784184</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2020 May 28;181(5):1036-1045.e9</Citation><ArticleIdList><ArticleId IdType="pubmed">32416070</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Discov. 2020 May 4;6:31</Citation><ArticleIdList><ArticleId IdType="pubmed">32377375</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 2020 Jun;178:104791</Citation><ArticleIdList><ArticleId IdType="pubmed">32275914</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Host Microbe. 2020 Jun 10;27(6):992-1000.e3</Citation><ArticleIdList><ArticleId IdType="pubmed">32320677</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Californie</li></region></list><tree><country name="États-Unis"><region name="Californie"><name sortKey="Mckechnie, Julia L" sort="Mckechnie, Julia L" uniqKey="Mckechnie J" first="Julia L" last="Mckechnie">Julia L. Mckechnie</name></region><name sortKey="Blish, Catherine A" sort="Blish, Catherine A" uniqKey="Blish C" first="Catherine A" last="Blish">Catherine A. Blish</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidStanfordV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000229 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000229 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidStanfordV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32464098
|texte= The Innate Immune System: Fighting on the Front Lines or Fanning the Flames of COVID-19?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32464098" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidStanfordV1
| This area was generated with Dilib version V0.6.38. |  |